CJC-1295 and Ipamorelin: How Growth Hormone Peptides Support Recovery and Anti-Aging
Among the many peptides used in regenerative and longevity medicine, the combination of CJC-1295 and Ipamorelin has emerged as one of the most widely prescribed and clinically studied. Together, these two peptides produce a synergistic stimulation of natural growth hormone (GH) release — restoring the pulsatile GH secretion pattern that declines progressively with age.
At Regen Health Physicians NYC, Dr. Ajit Dhaliwal prescribes CJC-1295/Ipamorelin as part of our peptide therapy program for patients seeking improved body composition, enhanced recovery, better sleep, and support for the physiological aspects of healthy aging. Understanding how these peptides work — and who benefits most — is essential before pursuing any growth hormone secretagogue protocol.
Why Growth Hormone Declines with Age
Growth hormone is produced by the pituitary gland in pulses — primarily during deep sleep. It acts on tissues throughout the body to:
- Stimulate protein synthesis and muscle repair
- Promote lipolysis (fat breakdown), particularly visceral fat
- Support connective tissue integrity — cartilage, tendon, skin collagen
- Modulate immune function
- Support cognitive function and neuroplasticity
- Regulate sleep architecture
After peak GH levels in the late teens and early twenties, secretion declines by approximately 14% per decade. By middle age, many adults produce 50–70% less GH than at their youthful peak. This decline — sometimes called somatopause — contributes to the progressive loss of lean muscle mass, increase in body fat, declining sleep quality, reduced recovery capacity, and accelerated tissue aging that characterize the second half of life.
What Are CJC-1295 and Ipamorelin?
CJC-1295 (with DAC)
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) — the hypothalamic signal that tells the pituitary to secrete growth hormone. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 8 days (versus the endogenous GHRH half-life of minutes), allowing for less frequent dosing while maintaining sustained pituitary stimulation.
CJC-1295 does not spike GH to supraphysiological levels — it amplifies the pulsatile pattern already present in your biology, producing a more robust but still natural GH release.
Ipamorelin
Ipamorelin is a GH secretagogue receptor agonist (GHRP) — a molecule that stimulates the pituitary through a different receptor pathway than CJC-1295. It is notable for its selectivity: it stimulates GH release with minimal effect on cortisol, prolactin, or ACTH, making it the cleanest and most well-tolerated GHRP available.
Ipamorelin has a short half-life (~2 hours) and produces a clean GH pulse corresponding to the injection.
Why Combine Them?
The combination of a GHRH analogue (CJC-1295) and a GHRP (Ipamorelin) is more potent than either used alone — the two pathways act synergistically in the pituitary to produce GH pulses significantly larger than what either achieves independently. This is the standard of care in peptide-based GH optimization protocols.
Clinical Benefits: What the Evidence and Clinical Experience Show
Improved Body Composition
Growth hormone is catabolic to adipose tissue and anabolic to lean mass. Patients on CJC-1295/Ipamorelin protocols typically observe:
- Gradual reduction in visceral and subcutaneous body fat over 3–6 months
- Improved muscle tone and recovery from resistance training
- Better muscle-to-fat ratio without the risks of exogenous human growth hormone (HGH)
Enhanced Recovery
For both athletic patients and those recovering from injury, improved GH secretion accelerates tissue repair. GH stimulates the production of IGF-1 (Insulin-Like Growth Factor 1) in the liver and locally in tissues — the primary anabolic mediator driving protein synthesis and cellular repair. Many patients report significantly improved recovery between training sessions. Our joint and orthopedic program sometimes incorporates peptide support for patients recovering from musculoskeletal injury or procedure.
Sleep Quality
Growth hormone secretion is maximally coupled to slow-wave (deep) sleep. The relationship is bidirectional: deep sleep drives GH release, and GH supports sleep architecture. Most patients on CJC-1295/Ipamorelin report meaningful improvement in sleep depth and subjective sleep quality within 2–4 weeks of starting — often described as the most immediately noticeable benefit.
Skin and Connective Tissue
GH and IGF-1 stimulate collagen and elastin synthesis. Patients typically notice improved skin texture and elasticity over several months. This also benefits joint and tendon health — a meaningful consideration for patients with chronic musculoskeletal conditions.
Cognitive Function and Wellbeing
Growth hormone receptors are expressed throughout the brain. GH and IGF-1 support neuroplasticity, neurotransmitter balance, and stress resilience. Patients often report improved mental clarity, sustained energy, and a generally heightened sense of wellbeing — benefits that are difficult to attribute to a single mechanism but are consistent across patient reports.
Protocol and Administration
At RHPNY, CJC-1295/Ipamorelin is typically prescribed as a subcutaneous injection administered before bed — the timing aligns with the natural nocturnal GH pulse and is well-tolerated in a home administration protocol. Dr. Dhaliwal provides comprehensive training and monitoring.
Our peptide therapy program always begins with a full evaluation:
- Baseline IGF-1 level (the primary lab marker of GH axis activity)
- Comprehensive metabolic, hormonal, and inflammatory panel
- Health history and goals assessment
Prescriptions are sourced exclusively from licensed compounding pharmacies meeting USP 797/800 standards.
Dosing is individualized. There is no single correct dose — IGF-1 levels, body weight, goals, and clinical response guide optimization.
Who Is the Right Candidate?
CJC-1295/Ipamorelin is best suited for:
- Adults over 35 experiencing progressive fatigue, reduced recovery, or declining body composition despite adequate diet and exercise
- Patients with documented low IGF-1 levels relative to age-matched norms
- Athletes seeking optimized recovery without prohibited substances
- Patients in active injury recovery where tissue repair support is desirable
- Those pursuing comprehensive anti-aging and longevity protocols alongside NAD+, hormone optimization, and other therapies
It is not appropriate for patients with active cancer (GH stimulation is contraindicated), pregnancy, uncontrolled diabetes, or severe pituitary disease.
Starting Peptide Therapy in NYC
Regen Health Physicians serves patients across New York City and Salt Lake City. If you're curious whether CJC-1295/Ipamorelin or another peptide protocol is appropriate for your health goals, the first step is a thorough consultation with Dr. Dhaliwal.
Book your consultation and begin building a personalized protocol grounded in your specific biology and objectives.
---
Medical Disclaimer: CJC-1295 and Ipamorelin are compounded peptide therapies. They are not FDA-approved for anti-aging or body composition purposes. Individual results vary. This content is for informational purposes only. Always consult a qualified physician before beginning peptide therapy.
